🤯 Picked by our AI, this stock rallied more than Nvidia this month, yielding 94% since MarchSee the stock

Qiagen to acquire diagnostics outfit STAT-Dx for up to $191M

Published 01/31/2018, 04:25 PM
© Reuters.  Qiagen to acquire diagnostics outfit STAT-Dx for up to $191M
QIA
-
  • QIAGEN (NASDAQ:QGEN) has agreed to acquire STAT-Dx, a pre-commercial-stage firm developing advanced multiplexed diagnostics for the molecular analysis of common syndromes, including serious respiratory and gastrointestinal infections. Its system, branded as QIAstat-Dx, is based on real-time PCR and can process up to 48 molecular targets simultaneously in less than one hour.
  • Under the terms of the agreement, Qiagen will pay $147M in upfront cash and up to $44M in regulatory and commercial milestones. The deal should close next quarter. Qiagen says the transaction will be dilutive to full-year 2018 non-GAAP EPS by ~$0.05 and neutral in 2019.
  • Now read: DiaMedica Therapeutics (DMCAF) - Presents At Noble Financial Capital Markets 14th Annual Investor Conference - Slideshow


Original article

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.